- Home
- XXII vs ALZN Comparison
XXII vs ALZN Comparison
Compare XXII & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- ALZN
- Stock Information
- Founded
- XXII 1998
- ALZN 2016
- Country
- XXII United States
- ALZN United States
- Employees
- XXII N/A
- ALZN N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- XXII Health Care
- ALZN Health Care
- Exchange
- XXII Nasdaq
- ALZN Nasdaq
- Market Cap
- XXII 2.0M
- ALZN 2.3M
- IPO Year
- XXII N/A
- ALZN 2021
- Fundamental
- Price
- XXII $2.43
- ALZN $2.35
- Analyst Decision
- XXII
- ALZN Strong Buy
- Analyst Count
- XXII 0
- ALZN 1
- Target Price
- XXII N/A
- ALZN $180.00
- AVG Volume (30 Days)
- XXII 2.7M
- ALZN 217.3K
- Earning Date
- XXII 08-14-2025
- ALZN 09-10-2025
- Dividend Yield
- XXII N/A
- ALZN N/A
- EPS Growth
- XXII N/A
- ALZN N/A
- EPS
- XXII N/A
- ALZN N/A
- Revenue
- XXII $23,869,000.00
- ALZN N/A
- Revenue This Year
- XXII $22.41
- ALZN N/A
- Revenue Next Year
- XXII $76.35
- ALZN N/A
- P/E Ratio
- XXII N/A
- ALZN N/A
- Revenue Growth
- XXII N/A
- ALZN N/A
- 52 Week Low
- XXII $2.18
- ALZN $2.06
- 52 Week High
- XXII $2,328.75
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- XXII 20.79
- ALZN 35.09
- Support Level
- XXII $2.18
- ALZN $2.14
- Resistance Level
- XXII $2.66
- ALZN $2.44
- Average True Range (ATR)
- XXII 0.31
- ALZN 0.17
- MACD
- XXII 0.33
- ALZN -0.03
- Stochastic Oscillator
- XXII 14.24
- ALZN 23.97
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.